Imugene Collaborates with JW Therapeutics on Innovative Cancer Treatment

TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off Imugene ( (AU:IMU) ) just unveiled an announcement. Imugene Limited announced a strategic collaboration with JW Therapeutics to advance the combination of onCARlytics (CF33-CD19) and Carteyva® for treating solid tumors. The collaboration includes a ‘mark and kill’ strategy for refractory solid tumors, potentially enhancing Imugene’s position in the immuno-oncology field. A webinar will be held to discuss this collaboration, indicating its significance for stakeholders and the company’s future operations. The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page. More about Imugene Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune system of cancer patients, aiming to treat and eradicate tumors. The company is working on a range of novel therapies, including an off-the-shelf CAR T drug targeting CD19 for blood cancers and oncolytic virotherapy for various cancers. Imugene is supported by a team of international cancer experts and aims to transform cancer treatment globally. Average Trading Volume: 2,331,149 Technical Sentiment Signal: Strong Sell Current Market Cap: A$99.33M See more insights into IMU stock on TipRanks’ Stock Analysis page.